Diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial
Jie Zang, Hao Wang, Jing-jing Zhang, Zhao-hui Zhu
PET Center, Department of Nuclear Medicine and Beijing Key Laboratory of Nuclear Medicine in Molecular Targeted Diagnosis and Therapy, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
|Date of Web Publication||30-Jan-2017|
PET Center, Department of Nuclear Medicine and Beijing Key Laboratory of Nuclear Medicine in Molecular Targeted Diagnosis and Therapy, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing
Source of Support: This study was supported by the Peking Union Medical College Scholar Project, China., Conflict of Interest: None
Background: Gastrin-releasing peptide receptor is particularly expressed in gliomas, while the peptide bombesin [BBN(7-14)] has the complete C-terminal structure of human gastrin-releasing peptide. Glioma-specific imaging agents can therefore be constructed from BBN, for example 68Ga-NOTA-Aca-BBN(7-14). For consideration of the clinical translation of 68Ga-NOTA-Aca-BBN(7-14), an open-label dynamic whole-body positron emission tomography/computed tomography (PET/CT) study was designed to investigate the diagnostic effectiveness and safety of 68Ga-NOTA-Aca-BBN(7-14) in patients with brain gliomas.
Methods/Design: This is an open-label single-arm clinical trial that will be conducted at Peking Union Medical College Hospital in Beijing, China. Thirty patients in suspicion of brain gliomas scheduled for surgical treatment will be recruited and subjected to PET/CT via intravenous injection of 68Ga-NOTA-Aca-BBN(7-14). The primary outcome measure will be the standardized uptake value of 68Ga-NOTA-Aca-BBN(7-14) in brain glioma at 30 minutes after injection. Secondary outcomes include the diagnostic accuracy rate of 68Ga-NOTA-Aca-BBN(7-14) PET/CT, and adverse events after injection.
Discussion: Diagnostic performance and safety assessment of 68Ga-NOTA-Aca-BBN(7-14) in brain gliomas will provide new insights into the specific PET/CT diagnosis of brain gliomas.
Trial registration: ClinicalTrials.gov identifier: NCT02520882, registered on 2 August 2015.
Ethics: This study protocol has been approved by the Ethics Committee of Peking Union Medical College Hospital in China (approval No. S-714), and will be performed in accordance with the Declaration of Helsinki, formulated by the World Medical Association.
Informed consent: An informed consent will be obtained from each patient or his/her guardian prior to participation in the study.
Keywords: clinical trial; 68Ga-NOTA-Aca-BBN(7-14); PET/CT; brain glioma; imaging agent; diagnosis; open-label clinical trial
|How to cite this article:|
Zang J, Wang H, Zhang Jj, Zhu Zh. Diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial. Asia Pac J Clin Trials Nerv Syst Dis 2017;2:23-9
|How to cite this URL:|
Zang J, Wang H, Zhang Jj, Zhu Zh. Diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial. Asia Pac J Clin Trials Nerv Syst Dis [serial online] 2017 [cited 2021 Jan 21];2:23-9. Available from: https://www.actnjournal.com/text.asp?2017/2/1/23/198959
| Introduction|| |
History and current studies
Gliomas arise from glial cells and are the most common primary tumor in the central nervous system (Mamelak and Jacoby, 2007; Brat et al., 2008), accounting for 27% of all central nervous system tumors and 80% of all malignant brain tumors (Goodenberger and Jenkins, 2012; Ostrom et al., 2015). The main clinical manifestations of gliomas are increased intracranial pressure and neurological deficit, and there may be a difficulty in distinguishing them from inflammation, demyelinating diseases, or leukoencephalopathy. Pathological evaluation is considered to be the gold standard for the diagnosis of glioma, but it is an invasive method, and moreover, the sites for pathological biopsies need to be previously determined using other methods. Therefore, noninvasive imaging has become the preferred clinical method for the diagnosis of glioma. Computed tomography (CT) and magnetic resonance imaging (MRI) are commonly used to diagnose intracranial lesions (Götz et al., 2012), but both of them have limitations in the assessment of benign and malignant tumors, and the biological behaviors of such tumors. Positron emission tomography (PET)/CT is an imaging method that combines structural imaging and functional imaging within a single procedure, and has demonstrated considerable advantages in the diagnosis of tumors. 18F-fluorodeoxyglucose (FDG) is the most widely used radioactive imaging agent in the PET/CT diagnosis of brain tumors; however, its usage is limited by the excessively high background concentration in brain tissue, non-specificity between inflammation and tumor uptake, and the blood glucose effect on 18F-FDG uptake (Dunet et al., 2012). There is therefore a considerable requirement for a new imaging agent suitable for the diagnosis of glioma.
Studies have shown that gastrin-releasing peptide receptor (GRPR) is distributed not only in glioma cell lines (Sharif et al., 1997; Farias et al., 2008), but also in glioma tissue sections from glioma patients (Flores et al., 2010). Various GRPR targeting imaging probes have therefore been developed as imaging agents for gliomas (Chen et al., 2004; Garrison et al., 2007; Carlucci et al., 2015). Bombesin (BBN) is an amphibian homolog of mammalian gastrin-releasing peptide (GRP) (Reubi et al., 2005; Zhang et al., 2006), and BBN(7-14), with an amino acid sequence of Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 has been extensively used for the development of molecular probes for the imaging of GRPR, after being labeled with various radionuclides (Chen et al., 2004; Smith et al., 2005; Prasanphanich et al., 2007; Mansi et al., 2011; Carlucci et al., 2015; Pourghiasian et al., 2015). Multiple preclinical studies have demonstrated receptor-specific accumulation of BBN imaging agents in GRPR positive tumors (Kunstler et al., 2007; Chatalic et al., 2014), and some of these imaging agents have been used in early clinical trials (Van de Wiele et al., 2001, 2008; Berthold and Theodosia, 2012; Ananias et al., 2013).
We aim to assess the diagnostic effectiveness and safety of 68Ga-NOTA-Aca-BBN(7-14) PET/CT in brain gliomas.
Novelty of this study
Most clinical imaging agent studies are based on 99mTc labeling and single photon emission computed tomography (SPECT) (Van de Wiele et al., 2000, 2001; Scopinaro et al., 2002a, b). In comparison with such techniques, PET imaging is characterized by higher sensitivity and spatial resolution. To date, PET imaging agents such as FDG, amino acid derivatives, thymidine analogues, and transporter targeting probes have been used in brain tumor imaging ([Table 1] and [Table 2]). BBN-based PET imaging agents are known to be useful for GRPR-targeted tumor imaging, and in this study we will examine the use of the GRPR specific imaging agent 68Ga-NOTA-Aca-BBN(7-14) for the diagnosis of brain gliomas.
|Table 1: Characteristics of existing clinical trials on PET/CT diagnosis of brain gliomas |
Click here to view
|Table 2: Clinical trials registered at ClinicalTrials.gov addressing biomarker and imaging analysis in traumatic brain injury |
Click here to view
| Methods/Design|| |
This open-label clinical trial, which includes recruitment, detection, and data analysis, will be conducted at Peking Union Medical College Hospital, Beijing, China.
Thirty patients in suspicion of brain gliomas scheduled for tumor resection will be recruited at Peking Union Medical College Hospital in China. PET/CT examination will be performed by intravenous injection of 68Ga-NOTA-Aca-BBN(7-14). The primary outcome measure will be the standardized uptake value (SUV) of 68Ga-NOTA-Aca-BBN(7-14) in brain gliomas, and the secondary outcome measures will include the diagnostic accuracy of 68Ga-NOTA-Aca-BBN(7-14) PET/CT in brain gliomas and adverse reactions within 1 week after imaging agent injection.
The study protocol is outlined in [Figure 1].
Patients who are highly suspected to have brain glioma and who are scheduled for tumor resection at Peking Union Medical College Hospital will be enrolled into this study.
Patients will be eligible for this trial if they meet all of the following conditions:
- Brain glioma as confirmed by MRI (Louis et al., 2007; Drafting Group for the China's Diagnosis and Treatment Guidelines for Gliomas in the Central Nervous System, 2016; the specific contents of which are shown in Additional file 1 [Additional file 1])
- Glioma resection and pathological examination
- An age of 30-70 years
Patients who meet any one of the following criteria will be excluded from the trial:
- Allergy or sensitivity to type IV imaging agent
- Inability to complete PET/CT scan due to cough and/or pain
- Inability to complete various examinations due to claustrophobia and radiation phobia
- Pregnant women or those at risk of pregnancy
Participants will be withdrawn from the trial if one of the following occurs:
- It is not possible to make an accurate therapeutic and safety judgment due to complications
- The patient is unable to complete a 1-year follow-up visit
In accordance with previous reports (Idema et al., 2012; Schwarzenberg et al., 2012; Karunanithi et al., 2013), a suitable sample size for this trial was identified as n = 30, which will be determined following the intention-to-treat principle.
The recruitment of patients who are highly suspected to have brain glioma and are scheduled for surgical treatment is ongoing at Peking Union Medical College Hospital. Patients or guardians who are interested in participation in the trial can contact the sponsor via telephone, e-mail, or WeChat. After providing written informed consent, patients will be screened according to the inclusion and exclusion criteria.
Baseline data, including demographical data, are shown in [Table 3].
Patients will be intravenously injected with 111-148 Mega-Becquerel (MBq)/kg 68Ga-NOTA-Aca-BBN(7-14) (provided by the Molecular Imaging and Nanomedicine Laboratory, National Institute of Health/National Institute of Biomedical Imaging and Bioengineering, USA), and low-dose CT (Siemens Medical Solutions, Erlangen, Germany) scans with parameters of 120 kV, 35 mA, 3-mm slice thickness, 512 × 512 matrix, and 70-cm field of view will be performed first, with whole-body PET (Siemens Medical Solutions) being performed 30 minutes after the administration of 68Ga-NOTA-Aca-BBN(7-14). Regions of interest will be drawn by two experienced nuclear medicine specialists, and the mean and maximum SUVs will be calculated from these regions of interest (Zhang et al., 2016).
The primary outcomes will be the mean and maximum SUVs of 68Ga-NOTA-Aca-BBN(7-14) in brain gliomas at 30 minutes after injection, with the SUV value being defined as the radioactivity concentration of the imaging agent in the lesions per unit volume/injected dose/body mass.
- Diagnostic accuracy of 68Ga-NOTA-Aca-BBN(7-14) PET/CT in brain gliomas: from a comparison of the diagnostic findings of 68Ga-NOTA-Aca-BBN(7-14) PET/CT with pathological results.
- Incidence of adverse reactions within 1 week after injection.
The time schedule for outcome assessments is shown in [Table 4].
Medical data will be collected and recorded in a case report form, both manually and electronically. Any alteration or correction will be recorded in detail.
Only authorized persons have the right to query the clinical data, in order to ensure security and confidentiality. All data relevant to this clinical trial will be preserved by Peking Union Medical College Hospital. Patient information will not be disclosed unless required by law. Research findings will be published for scientific purposes without disclosing the patient's identity, and published data will be released at http://www.figshare.com.
Measurement data will be expressed as the mean ± SD, and enumeration data expressed as percent.
| Trial Status|| |
Recruitment is ongoing at the time of submission.
Pre-test results from Zhao-hui Zhu's team addressing different imaging agents in the PET/CT diagnosis of gliomas are shown in [Table 5].
|Table 5: Research findings concerning different imaging agents in the PET/CT diagnosis of gliomas published by Zhao-hui Zhu's team |
Click here to view
| Discussion|| |
Significance of this study
Unspecific imaging agents, such as 18F-thymidine, have been used in most existing studies addressing the PET diagnosis of gliomas. The current study will attempt to observe the effect of 68Ga-NOTA-Aca-BBN(7-14), a GRPR-specific imaging agent, in the PET diagnosis of brain glioma. Studies have shown the presence of GRPR in brain glioma, but not in normal brain tissues, and moreover, GRPR antagonists are pathologically confirmed to inhibit glioma (Pinski et al., 1994; Kiaris et al., 1999; de Oliveira et al., 2009). On the basis of this knowledge, the non-invasive imaging evaluation of GRPR expression will be of great help in drug development, patient stratification, and therapeutic response monitoring.
Outcome evaluation will be limited by the small sample size, lack of a comparison with other metastatic tumors similar to brain glioma and non-neoplastic lesions, and the lack of a comparison with other imaging agents. Therefore, further studies will be needed to determine the application value of 68Ga-NOTA-Aca-BBN(7-14) PET/CT in gliomas.
Contribution to future studies
Through the 1-year follow-up, our outcomes concerning the diagnostic safety and effectiveness of PET/CT in brain glioma patients will provide new insights into glioma-specific PET/CT diagnosis.
Additional file 1: MRI diagnostic criteria for gliomas (Louis et al., 2007; Drafting Group for the China's Diagnosis and Treatment Guidelines for Gliomas in the Central Nervous System, 2016).
| References|| |
Ananias HJK, Yu Z, Hoving HD, Rosati S, Dierckx RA, Wang F, Yan Y, Chen X, Pruim J, Lub-de Hooge MN, Helfrich W, Elsinga PH, de Jong IJ (2013) Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study. Nucl Med Biol 40:933-938.
Berthold AN, Theodosia M (2012) Tetraamine-coupled peptides and resulting (99m)Tc-radioligands: an effective route for receptor-targeted diagnostic imaging of human tumors. Curr Top Med Chem 12:2655-2667.
Brat DJ, Prayson RA, Ryken TC, Olson JJ (2008) Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 89:287-311.
Carlucci G, Kuipers A, Ananias HJ, de Paula Faria D, Dierckx RA, Helfrich W, Rink R, Moll GN, de Jong IJ, Elsinga PH (2015) GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs. Peptides 67:45-54.
Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M (2014) Preclinical comparison of Al 18
F- and 68
Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J Nucl Med 55:2050-2056.
Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS (2004) microPET and Autoradiographic Imaging of GRP Receptor Expression with 64
Cu-DOTA-[Lys3]Bombesin in Human Prostate Adenocarcinoma Xenografts. J Nucl Med 45:1390-1397.
de Oliveira MS, Cechim G, Braganhol E, Santos DG, Meurer L, de Castro CG, Brunetto AL, Schwarstmann G, Battastini AMO, Lenz G, Roesler R (2009) Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol 93:191-201.
den Hollander MW, Bensch F, Glaudemans AW, Oude Munnink TH, Enting RH, den Dunnen WF, Heesters MA, Kruyt FA, Lub-de Hooge MN, Cees de Groot J, Pearlberg J, Gietema JA, de Vries EG, Walenkamp AM (2015) TGF-β antibody uptake in recurrent high-grade glioma imaged with 89
Zr-fresolimumab PET. J Nucl Med 56:1310-1314.
Drafting Group for the China′s Diagnosis and Treatment Guidelines for Gliomas in the Central Nervous System, (2016) China′s Diagnosis and Treatment Guidelines for Gliomas in the Central Nervous System (2015 Edition). Zhonghua Yixue Zazhi 96:485-509.
Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012) Performance of 18
F-fluoro-ethyl-tyrosine ( 18
F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 53:207-214.
Enslow MS, Zollinger LV, Morton KA, Kadrmas DJ, Butterfield RI, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM (2012) Comparison of 18
F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 37:854-861.
Farias CB, Lima RC, Lima LO, Flores DG, Meurer L, Brunetto AL, Schwartsmann G, Roesler R (2008) Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling. Oncology 75:27-31.
Flores DG, Meurer L, Uberti AF, Macedo BR, Lenz G, Brunetto AL, Schwartsmann G, Roesler R (2010) Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull 82:95-98.
Götz L, Spehl TS, Weber WA, Grosu AL (2012) PET and SPECT for radiation treatment planning. Q J Nucl Med Mol Imaging 56:163-172.
Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, Hoffman TJ (2007) In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 48:1327-1337.
Goodenberger ML, Jenkins RB (2012) Genetics of adult glioma. Cancer Genet 205:613-621.
Idema AJ, Hoffmann AL, Boogaarts HD, Troost EG, Wesseling P, Heerschap A, van der Graaf WT, Grotenhuis JA, Oyen WJG (2012) 3′-Deoxy-3′- 18
F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med 53:1904-1910.
Jeong SY, Lim SM (2012) Comparison of 3′-deoxy-3′-[18F]fluorothymidine PET and O-(2-[ 18
F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol 39:977-981.
Kameyama M, Ishiwata K, Tsurumi Y, Itoh J, Sato K, Katakura R, Yoshimoto T, Hatazawa J, Ito M, Ido T (1995) Clinical application of 18
F-FUdR in glioma patients--PET study of nucleic acid metabolism. J Neurooncol 23:53-61.
Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, Gupta DK, Malhotra A, Bal C (2013) 18
F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18
F-FDG PET/CT. Eur J Nucl Med Mol Imaging 40:1025-1035.
Kiaris H, Schally AV, Sun B, Armatis P, Groot K (1999) Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide. Oncogene 18:7168-7173.
Kunstler JU, Veerendra B, Figueroa SD, Sieckman GL, Rold TL, Hoffman TJ, Smith CJ, Pietzsch HJ (2007) Organometallic 99m
Tc(III) ′4 + 1′ bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjug Chem 18:1651-1661.
Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, Wang J, Kang P, Liu Z, Shi J, Chen X, Zhu Z (2014) (68)Ga-PRGD2 PET/CT in the evaluation of Glioma: a prospective study. Mol Pharm 11:3923-3929.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109.
Mamelak AN, Jacoby DB (2007) Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv 4:175-186.
Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38:97-107.
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 17 Suppl 4:iv1-iv62.
Pöpperl G, Götz C, Rachinger W, Gildehaus F-J, Tonn JC, Tatsch K (2004) Value of O-(2-[18
F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464-1470.
Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K (1994) Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 54:5895-5901.
Pourghiasian M, Liu Z, Pan J, Zhang Z, Colpo N, Lin K-S, Perrin DM, Bénard F (2015) 18
: A novel radiofluorinated bombesin derivative for prostate cancer imaging. Biorg Med Chem 23:1500-1506.
Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, Hoffman TJ, Sieckman GL, Figueroa SD, Smith CJ (2007) [(64)Cu-NOTA-8-Aoc-BBN(7-14)NH(2)] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 104:12462-12467.
Reubi JC, Mäcke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46:67S-75S.
Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W (2012) 3′-deoxy-3′- 18
F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53:29-36.
Scopinaro F, Varvarigou AD, Ussof W, De Vincentis G, Sourlingas TG, Evangelatos GP, Datsteris J, Archimandritis SC (2002a) Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm 17:327-335.
Scopinaro F, Varvarigou A, Ussof W, De Vincentis G, Archimandritis S, Evangelatos G, Corleto V, Pulcini A, Capoccetti F, Remediani S, Massa R (2002b) Breast cancer takes up 99m
Tc bombesin. A preliminary report. Tumori 88:S25-28.
Sharif TR, Luo W, Sharif M (1997) Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol Cell Endocrinol 130:119-130.
Smith CJ, Volkert WA, Hoffman TJ (2005) Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32:733-740.
Tsuchida T, Takeuchi H, Okazawa H, Tsujikawa T, Fujibayashi Y (2008) Grading of brain glioma with 1- 11
C-acetate PET: comparison with 18
F-FDG PET. Nucl Med Biol 35:171-176.
Van de Wiele C, Dumont F, Dierckx RA, Peers SH, Thornback JR, Slegers G, Thierens H (2001) Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med 42:1722-1727.
Van de Wiele C, Phonteyne P, Pauwels P, Goethals I, Van den Broecke R, Cocquyt V, Dierckx RA (2008) Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med 49:260-264.
Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA (2000) Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 27:1694-1699.
Zhang J, Li D, Lang L, Zhu Z, Wang L, Wu P, Niu G, Li F, Chen X (2016) 68
Ga-NOTA-Aca-BBN(7-14) PET/CT in healthy volunteers and glioma patients. J Nucl Med 57:9-14.
Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, Xing L, Chen X (2006) 18
F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 47:492-501.
Declaration of patient consent
The authors certify that they will obtain all appropriate patient consent forms. In the form the patients will give their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Conflicts of interest
JZ and HW will implement the trial. JJZ will be responsible for coordination and assistance. ZHZ will be responsible for study design, analysis and summarization. All authors have approved the final version of the paper.
This paper was screened twice using CrossCheck to verify originality before publication.
This paper was double-blinded and stringently reviewed by international expert reviewers.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]